Based on our multiplex antibody array data as well as our immuno-fluorescence data; caspase 3 was being cleaved (activated) after drug combination treatment, and we next investigated the molecular mechanisms by which (ruxolitinib + ERBB1/2/4 inhibitor) was killing tumor cells. This evidence concerns the gene CASP3 and neoplasm.